98%
921
2 minutes
20
Sepsis is a complex condition of inflammatory and immune dysregulation, triggered by severe infection. In survivors, chronic inflammation and immune dysregulation linger, facilitating the emergence of infections. CD8 dysfunction contributes to immunosuppression in sepsis survivors. We devised an animal model that enabled us to identify and analyze CD8-intrinsic defects induced by sepsis. We adoptively transferred CD45.1 CD8 OT-I T cells into CD45.2 congenic mice and subjected them to cecal ligature and puncture, to induce abdominal sepsis. One month later, we isolated the transferred CD8 cells. Surface marker expression confirmed they had not been activated through the TCR. CD8 OT-I T cells isolated from septic (or sham-operated) mice were transferred to second recipients, which were challenged with OVA-expressing Listeria monocytogenes. We compared effector capacities between OT-I cells exposed to sepsis and control cells. Naive mice that received OT-I cells exposed to sepsis had higher bacterial burden and a shorter survival when challenged with OVA-expressing L. monocytogenes. OT-I cells isolated from septic mice produced less IFN-γ but had conserved activation, expansion potential, and cytotoxic function. We observed lower transcript levels of IFN-γ and of the long noncoding RNA Ifng-as1, a local regulator of the epigenetic landscape, in cells exposed to sepsis. Accordingly, local abundance of a histone modification characteristic of active promoter regions was reduced in sepsis-exposed CD8 T cells. Our results identify a mechanism through which inflammation in the context of sepsis affects CD8 T cell function intrinsically.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4049/jimmunol.2300772 | DOI Listing |
J Immunol
September 2025
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States.
Transforming growth factor beta (TGFβ) is an immunosuppressive cytokine that is overexpressed in tumor microenvironments. We have shown that CD8+ T cells with genetic ablation of the TGFβ type I receptor, Alk5 (CD8ΔALK5), were more sensitive to αCD3 stimulation resulting in enhanced proliferation and cytokine production. Based on these data, we hypothesized that TGFβ impaired T-cell receptor (TCR) signaling.
View Article and Find Full Text PDFFront Immunol
September 2025
Division of Vaccinology for Clinical Development, Institute for Vaccine Research and Development, Hokkaido University (HU-IVReD), Sapporo, Japan.
Background: Memory CD8 T cells sense inflammation and rapidly produce interferon-γ (IFN-γ) independent of cognate antigens. This innate-like property, called bystander activation, is involved in early host defense before the antigen-specific memory response. However, the molecular mechanisms underlying this activation remain unknown.
View Article and Find Full Text PDFAllergy
August 2025
Centre for Inflammation Research, Institute for Regeneration and Repair, the University of Edinburgh, Edinburgh, Scotland.
Background: Viral lower respiratory tract infections (LRTIs) can reduce the severity of subsequent LRTIs but have also been linked to respiratory allergy development and exacerbation. Here, we show that viral LRTI can imprint lung epithelial cells (LECs), leading to prolonged phenotypic and functional changes.
Methods: Mice were infected via intranasal administration of respiratory syncytial virus (RSV).
Int Immunopharmacol
July 2025
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China. Electronic address:
Probiotic Lactococcus lactis (L.L) can act as an antigen delivery carrier to cross-present (XPT) exogenous antigens in dendritic cells (DCs). To optimize antigen XPT in a DC-based vaccine for improved antitumor efficacy, we produced recombinant L.
View Article and Find Full Text PDFBr J Cancer
July 2025
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.
Background: Elevating major histocompatibility complex class I (MHC-I) levels in tumour cells can boost antitumour immunity and enhance immunotherapy for colorectal cancer (CRC). Screening an FDA-approved drug library showed that MEK inhibitors (MEKis) significantly increase MHC-I expression in CRC cells, though the mechanisms and antitumour effects of MEKis, as well as their impact on gut microbiota, remain unclear.
Methods: Dual-luciferase reporter system was employed to screen MHC-I inducers.